Posted by Aston Avery

World Laboratory Day

Today on World Laboratory Day 2024, we’re highlighting the significant strides made in treating erythropoietic protoporphyria (EPP), a rare and debilitating condition causing severe sensitivity to light. Pioneering these efforts, CLINUVEL provides a vital treatment through SCENESSE┬« (afamelanotide), a drug that has transformed the lives of EPP patients by enabling them to withstand light exposure and significantly improving their daily lives.

Turning our focus to vitiligo, a common and visually striking skin depigmentation disease, CLINUVEL is at the forefront of new treatments. Their ongoing Phase III study addresses this condition, which disproportionately affects individuals with darker skin and carries a heavy psychological burden. Recognized by the U.S. FDA for prioritized treatment, this research underscores the urgent need for effective solutions in vitiligo care.

Aston spoke to Dr Philippe Wolgen, CEO of CLINUVEL.

Ads help us keep this site online